Pre‐treatment health‐related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma. The Nordic Lymphoma Group MCL4 (LENA‐BERIT) experience.
Source : https://onlinelibrary.wiley.com/doi/10.1002/hon.2940
Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality...
Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34710755/
Taken together, MYR is an oral available natural BTK inhibitor that effectively inhibits the growth of lymphoma TMD-8 cells both in vitro and in vivo. In addition, our findings support...
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukaemia management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34713475/
Targeted therapies have dramatically transformed the CLL treatment landscape. Two treatment paradigms have emerged using B-cell lymphoma 2 inhibitors (BCL2i) and Bruton's tyrosine kinase (BTK): (i) fixed duration and (ii)...
Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34651428/
Mantle cell lymphoma (MCL) is a haematologic malignancy. The proteasome inhibitor (PI) bortezomib has been approved to treat MCL, but resistance has emerged through mechanisms that remain unclear. This study...
Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL
Building on the progress made in chronic lymphocytic leukemia (CLL) treatment with ibrutinib, second-generation Bruton tyrosine kinase (BTK) inhibitors continue to be studied in ongoing trials in an attempt to...